Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Interest & Investment Income (2021 - 2025)

Historic Interest & Investment Income for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $74379.0.

  • InMed Pharmaceuticals' Interest & Investment Income rose 14357.81% to $74379.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $236396.0, marking a year-over-year decrease of 2440.84%. This contributed to the annual value of $155882.0 for FY2025, which is 7047.14% down from last year.
  • InMed Pharmaceuticals' Interest & Investment Income amounted to $74379.0 in Q4 2025, which was up 14357.81% from $93765.0 recorded in Q3 2025.
  • In the past 5 years, InMed Pharmaceuticals' Interest & Investment Income ranged from a high of $166760.0 in Q4 2023 and a low of $5148.0 during Q3 2021
  • For the 5-year period, InMed Pharmaceuticals' Interest & Investment Income averaged around $80025.4, with its median value being $73483.0 (2022).
  • In the last 5 years, InMed Pharmaceuticals' Interest & Investment Income soared by 131000.39% in 2022 and then tumbled by 8636.15% in 2025.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Interest & Investment Income stood at $26277.0 in 2021, then surged by 340.68% to $115797.0 in 2022, then soared by 44.01% to $166760.0 in 2023, then tumbled by 81.69% to $30536.0 in 2024, then surged by 143.58% to $74379.0 in 2025.
  • Its last three reported values are $74379.0 in Q4 2025, $93765.0 for Q3 2025, and $51687.0 during Q2 2025.